NRX PHARMACEUTICALS INC (NRXP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.49+1.75%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NRXP
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||
| Revenues | 3.4 | 1.2 | 0.0 | 0.0 | — | — | — | — | — | — |
| Cost of Revenues | 1.8 | 0.5 | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||
| Selling, General & Admin | 15.9 | 13.1 | — | — | — | — | — | — | — | — |
| R&D Expenses | 5.4 | 3.8 | 6.2 | 13.4 | 17.0 | 20.3 | 10.6 | — | — | — |
| Operating Income | (19.9) | (16.2) | (18.5) | (27.8) | (44.3) | (115.8) | (51.4) | (0.7) | (1.0) | — |
| Earnings from Continuing Operations | ||||||||||
| Interest Expense | — | 0.7 | 0.2 | 0.1 | — | 0.0 | 0.1 | — | — | — |
| Interest & Investment Income | 0.0 | 0.0 | 0.0 | 0.5 | — | — | — | — | — | — |
| Net Interest Expenses | — | — | — | (0.4) | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | (3.6) | (12.4) | (6.6) | (2.3) | 4.6 | 22.7 | (0.4) | — | 1.1 | — |
| EBT, Incl. Unusual Items | — | — | — | — | (39.8) | (93.1) | (51.8) | 0.5 | 0.1 | — |
| Income Tax Expense | — | 0.0 | 0.0 | 0.0 | — | — | 0.0 | 0.1 | 0.0 | — |
| Net Income | ||||||||||
| Net Income | (23.5) | (28.6) | (25.1) | (30.2) | (39.8) | (93.1) | (51.8) | 0.4 | 0.1 | — |
| Per Share | ||||||||||
| Basic EPS | (0.62) | (1.34) | (2.36) | (3.98) | (0.60) | (1.98) | (1.51) | — | — | — |
| Diluted EPS | — | — | — | — | (0.60) | (1.98) | (1.51) | — | — | — |
| Basic Weighted Avg Shares | 37.6 | 21.4 | 10.6 | 7.6 | 65.8 | 46.9 | 34.3 | — | — | — |
| Diluted Weighted Avg Shares | — | — | — | — | 65.8 | 46.9 | 34.3 | — | — | — |
| Supplemental | ||||||||||
| EBITDA | — | (16.2) | — | — | — | — | — | — | — | — |
| EBIT | (19.9) | (16.2) | (18.5) | (27.8) | (44.3) | (115.8) | (51.4) | (0.7) | (1.0) | — |
| Effective Tax Rate | — | — | — | — | — | — | -0.0% | 17.1% | 19.8% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.